1. What is Huons?
Huons is a company demonstrating stable growth across diverse sectors, including pharmaceuticals, beauty & wellness, and contract manufacturing (CMO). Notably, hit products like ‘Menolacto’ have solidified its position in the beauty & wellness market.
2. What Happened in Q1 2025?
Huons recorded impressive growth in Q1 2025, with revenue of ₩156 billion, operating profit of ₩13.1 billion, and net income of ₩11.6 billion. This represents a 6.9% year-over-year increase in revenue, a 2.3% increase in operating profit, and a surge of over 2.9 times in net income.
3. What’s Behind the Strong Performance?
- Consistent Growth in Core Businesses: Huons maintained steady growth across all sectors, including pharmaceuticals, beauty & wellness, and CMO.
- Efficient Cost Management: Improved cost of goods sold and streamlined selling, general, and administrative expenses significantly boosted profitability.
- Strategic Investments: Investment in PanGen Biotech has secured future growth engines, including entry into the biosimilar market.
- Business Restructuring: The merger of the health functional food division has strengthened business efficiency.
4. What Should Investors Do?
Huons’ strong Q1 performance signals positive growth prospects. Experts maintain a ‘buy’ rating on Huons stock, suggesting its consistent growth and future value warrant consideration for active investment.